<DOC>
	<DOCNO>NCT01236716</DOCNO>
	<brief_summary>This trial study efficacy nab-PC vs. GC evaluate toxicity nab-PC advanced squamous cell cancer lung . The correlation efficacy nab-PC biomarkers also evaluate .</brief_summary>
	<brief_title>Nab-Paclitaxel Treatment Advanced Squamous Cell Carcinoma Lung</brief_title>
	<detailed_description>Albumin-bound paclitaxel ( nab-P ) utilize albumin binding protein , ( gp60 ) /caveolin-1 ( CAV1 ) SPARC ( secrete protein acidic rich cysteine ) , achieve high intratumoral paclitaxel accumulation . It report CAV1 overexpressed squamous cell cancer ( SQC ) , possible nab-PC highly active GC SQC lung .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Previously untreated , histological document stage IIIB ( amenable radical regional therapy ) stage IV squamous cell carcinoma lung . At least one measurable lesion define RECIST criterion . At least 18 year age . ECOG PS 0~1 Patients previously malignant tumor history except cured cervical carcinoma situ , basal cell carcinoma superficial bladder cancer . Patients also eligible receive chemotherapy regimen neoadjuvant adjuvant chemotherapy disease recur 12 month since finish neoadjuvant adjuvant chemotherapy . neutrophil ≥ 1.5 x 109 /L , Hemoglobin &gt; 90 g/L , Platelet count &gt; 100x109/L . Total bilirubin ≤ 1.5 x upper limit normal . ALT AST &lt; 2.5 x upper limit normal without liver metastasis , ALT AST &lt; 5 x upper limit normal liver metastasis . Serum creatinine &lt; 1.5 x upper limit normal . Urine pregnancy test negative woman . Estimated life expectancy least 3 month . Patient comply clinical trial protocal . Informed consent must sign . Patients currently undergo antitumor therapy . Patients enrol clinical trial within 4 week study entry . Any physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use study medication render subject high risk treatment . Central nervous system ( CNS ) tumor metastatic tumor . Serious mental disorder . Serious dysgnosia . Other serious comorbidity . Alcohol drug dependence . Previously allergic drug use study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>squamous cell carcinoma lung</keyword>
	<keyword>Albumin bound paclitaxel</keyword>
	<keyword>chemotherapy</keyword>
</DOC>